Advaxis receives DSMB authorization to complete dosing in first leg of ADXS11-001 cervical dysplasia clinical trial The science team from Advaxis, Inc., , the live, attenuated Listeria monocytogenes immunotherapy business, met with the Data Safety Monitoring Panel , an independent group of doctors, yesterday and received approval to dose all remaining patients in the original forty patient leg of the 120-patient, cervical dysplasia scientific trial being conducted in the United States. The DSMB found no safety issues that warranted any noticeable change in the conduct of the trial.S. Food and Drug Administration. The protocol, decided to by the FDA, needed that an initial band of individuals end up being treated and assessed by a DSMB ahead of enrolling the entire complement of patients in each forty affected person group.And the Journal of Hypertension in Europe. They will also appear in medical journals across Latin America and have been endorsed by the Asian Pacific Society of Hypertension. The guidelines have been translated to French currently, Creole and Spanish, and there are plans to keep translations for populations around the world. 'These guidelines have already been written to offer a straightforward approach to managing hypertension in the community. We are therefore proud to have created a set of guidelines that will help not merely doctors but also individuals understand their disease and the treatment they receive,' says Dr.